Neuren Pharmaceuticals (ASX: NEU) Raises 2026 Income Outlook to US$93 Million, but How Much Is Recurring?

Neuren Pharmaceuticals Limited (ASX: NEU) is heading towards a record year for income from its licensed Rett syndrome treatment, with stronger DAYBUE sales and a European milestone lifting its 2026 outlook to US$91 million to US$93 million.

The 5 November update strengthens Neuren's commercial position, but it also raises an important question: how much of this income represents sustainable royalty growth rather than one-off payments?

Key Numbers

• US$140 million: DAYBUE global net sales in Q3 2026, up 39% year-on-year.
• US$16.4 million: Neuren's Q3 royalty income, up 51% year-on-year.
• US$505 million to US$520 million: Acadia's upgraded 2026 global DAYBUE sales guidance.
• US$91 million to US$93 million: Neuren's revised 2026 trofinetide income guidance, including milestones.
• US$35 million: European commercial launch milestone earned following DAYBU's launch in Germany.

DAYBUE Sales Growth Drives Upgraded Guidance

The latest development follows another strong quarter from Neuren's commercial partner, Acadia Pharmaceuticals (Nasdaq: ACAD).

DAYBUE global net sales increased 12% from the June quarter, supported by growing uptake of DAYBUE STIX, a powder formulation introduced to provide patients with another administration option.

Acadia consequently upgraded its full-year sales guidance from US$480 million to US$510 million to a revised range of US$505 million to US$520 million.

For Neuren, expected full-year royalty income has increased from US$53 million to US$56 million to approximately US$56 million to US$58 million.

The larger increase in total trofinetide income reflects the US$35 million milestone earned following the first European commercial sale in Germany during October.

While the milestone strengthens Neuren's financial position, it is non-recurring. Continued royalty expansion will therefore be more important when assessing sustainable earnings.

What Stands Out to Us

Neuren's licensing arrangement gives it an attractive commercial structure.

Acadia is responsible for trofinetide commercialisation, allowing Neuren to earn royalties without independently funding a global sales and distribution network.

The company's intellectual property position has also strengthened, with an additional US patent allowance extending protection for DAYBUE and DAYBUE STIX through March 2041.

However, commercial success has not translated directly into higher accounting profits.

Neuren reported first-half 2026 profit after tax of A$4.9 million, down from A$15.0 million a year earlier, as research and development spending increased to A$27.4 million.

Operating cash inflow was A$8.0 million, although the prior corresponding period benefited from substantial non-recurring licensing receipts.

With A$286.5 million in cash and short-term investments at 30 June 2026, Neuren has substantial financial flexibility. Its valuation nevertheless depends on future royalty growth and the commercial potential of its development pipeline, not simply the latest milestone payment.

What Neuren Is Doing Now

Neuren is advancing NNZ-2591, also known as ercanetide, through its Koala Phase 3 trial for Phelan-McDermid syndrome, while Acadia expands trofinetide's international reach.

On 2 November, Neuren received US orphan drug designation for NNZ-2591 in hypoxic-ischaemic encephalopathy, potentially providing regulatory development incentives but not establishing clinical effectiveness.

Acadia has also completed its Japanese Phase 3 Rett syndrome study, with results supporting a planned regulatory filing in 2027 and a potential launch in 2028, subject to approval.

Neuren's first-ever dividend program, introduced in August, provides another indication of its transition towards a royalty-supported business.

Insight: Can Recurring Royalties Support Neuren's Valuation?

We think Neuren's strongest advantage is its combination of growing commercial royalties, substantial liquidity and a potentially valuable clinical pipeline. DAYBUE's international expansion creates opportunities to diversify revenue beyond the US market, while extended patent protection supports its longer-term commercial position. Nevertheless, the US$35 million European milestone should not be confused with recurring earnings. Neuren's valuation must also accommodate considerable clinical development uncertainty. Our assessment remains constructive on the business model, but sustained royalty growth, disciplined research spending and credible Phase 3 progress are necessary to support longer-term expectations.

What Happens Next?

The immediate test is whether Acadia delivers its upgraded 2026 sales guidance while maintaining momentum in DAYBUE STIX adoption.

A further potential catalyst is Neuren's US$50 million North American sales milestone, payable when annual net sales in that territory reach the relevant US$500 million threshold. Acadia's global guidance alone does not establish that the regional threshold will be met.

European uptake, Japan's planned regulatory submission and progress in the Koala Phase 3 trial will also shape the outlook.

For Neuren, the central question is shifting from whether DAYBUE can generate meaningful revenue to how reliably that revenue can support earnings, clinical development and shareholder distributions over time.